Unlock instant, AI-driven research and patent intelligence for your innovation.

HIV (human immunodeficiency virus) microbicide and application thereof

A microbicide, HIV-1 technology, applied in the field of HIV infection prevention, can solve problems such as increasing HIV infection

Inactive Publication Date: 2013-08-14
TIANJIN FUSOGEN BIOTECH CO LTD +1
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] The first HIV microbicide to enter phase III clinical trials is N-9, which has been marketed as a spermicide for many years. Unfortunately, clinical research results show that N-9 does not block or reduce HIV infection as expected , but increased the probability of HIV infection to a certain extent (HillierSL et al., 2005, AIDS and Human Retrovirology Journal (J Acquir Immune Defic Syndr) 39 (1): 1-8)
So far, there is no HIV microbicide on the market in the world

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • HIV (human immunodeficiency virus) microbicide and application thereof
  • HIV (human immunodeficiency virus) microbicide and application thereof
  • HIV (human immunodeficiency virus) microbicide and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1-Sifuvirtide Gel Cell Level Anti-HIV-1 Pseudovirus Activity Test

[0040] Sifuvirtide was dissolved in sterile PBS solution (pH=7.4), or dissolved in 0.0015% hydroxyethylcellulose (HEC) gel. Four HIV-1 Env-pseudoviruses were produced in 293T cells by co-transfection of different subtypes of HIV env expression plasmids with the HIV-1 backbone plasmid pNL4-3Δenv (including all HIV-1 genomes except Env) Among them, the HIV env expression plasmids of four different subtypes are encoding HIV-1 SVPB16 (B subtype), SVPC12 (C subtype), 32-72 (CRF07_BC) and SH188.6 (CRF01_AE) viral strain envelopes albumen. Pseudoviruses were collected and stored at -80°C after titration.

[0041] The specific method is as follows, on a 96-well plate, about 1×10 per well 4 TZM-bl cells were plated and cultured at 37°C for one day in DMEM (Dulbecco's Modified Eagle Medium) medium containing 10% bovine fetoprotein and penicillin-streptomycin. Pseudovirus (per hole 100TCID 50 ) and th...

Embodiment 2

[0043] Example 2-Sifuvirtide Gel In Vitro Safety Evaluation

[0044] In vitro safety evaluation using cell models. Three different concentrations of SFT (3 nM, 30 nM and 300 nM) in 0.015% HEC gel and PBS solutions were prepared. The effect of the above samples on the viability of Caco-2 rectal epithelial cells or macrophage RAW264.7 was detected by MTT colorimetry.

[0045] Follow the method of Denizot and Lang, in simple terms, 5×10 4 ml -1 The cells were seeded in 96-well plates in 0.015% HEC gel containing different concentrations (3nM, 30nM and 300nM) of SFT or SFT in PBS solution, 37°C, humidified 5% CO 2 After culturing for 12 hours under the condition, 50 μl of cells were collected and stored at -80° C., pending further determination of cytokine content. After the remaining samples were cultured for 48 hours, 10 μl of MTT (5 mg / ml) was added to the culture plate and incubated at 37° C. for 4 hours. Then, the medium was removed and formazan was dissolved in acidifie...

Embodiment 3

[0048] Example 3-Safety test of sifuvirtide in mice

[0049] The BALB / c female mice without pathogens of 6-8 weeks were randomly divided into 8 groups, 5 in each group, and 40 μ l of pH 4.5 containing 1.5% HEC gel (placebo control), respectively containing three 1.5% HEC gel, 1% TFV, 3% carrageenan, 6% CS, 1% N-9 gel with various concentrations of SFT (0.03mM, 0.3mM, 3mM). Continuous vaginal administration for 3 days, once every 12 hours. Twelve hours after the last administration, rinse the cervix and vagina with 200 μl sterile normal saline and collect the lavage fluid, then treat the lavage fluid with protease inhibitors (Complete Protease Inhibitor Cocktail, Roche), and centrifuge at 200×g for 10 minutes at 4°C , the supernatant was collected and stored at -80°C for use in the determination of cytokines. After the mice were sacrificed, the vaginal tissues were collected for further mononuclear cell isolation or histological examination.

[0050] Mouse reproductive tract...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an HIV (human immunodeficiency virus) microbicide. The microbicide contains sifuvirtide and a medicine for preventing or treating AIDS (acquired immune deficiency syndrome), and can be a reverse transcriptase inhibitor. The invention also relates to a method for preventing HIV-1 infection. The method involves an effective dose of HIV microbicide in the claim 1 through a mammal mucosa.

Description

technical field [0001] The present invention relates to an HIV microbicide and a method for preventing HIV infection by vaginal or rectal administration. Background technique [0002] 1. AIDS epidemic trend [0003] Since the first case of AIDS infection was discovered in 1981, AIDS has become a global health problem due to its rapid spread, high fatality rate and incurability. Although the promotion of cocktail therapy has greatly reduced the morbidity and mortality of AIDS, its harmfulness cannot be underestimated. As of 2009, 30 million people in the world have died from AIDS-related diseases, and there are more than 33.4 million surviving human immunodeficiency virus (HIV) infected and AIDS patients, and about 7,000 people are found to be newly infected with HIV every day ( www.unaids.org ). In my country, as of the end of October 2011, a total of 434,000 HIV-infected and patients were reported nationwide, including 166,000 patients and 88,000 deaths. [0004] About...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/16A61P31/18A61K31/675
CPCA61K38/16A61P31/18
Inventor 张晓燕李亮助徐建青贲银银姜世勃齐敬总陈昕
Owner TIANJIN FUSOGEN BIOTECH CO LTD